These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21664218)

  • 41. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague.
    Garmory HS; Griffin KF; Brown KA; Titball RW
    Vaccine; 2003 Jun; 21(21-22):3051-7. PubMed ID: 12798649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.
    Quenee LE; Ciletti NA; Elli D; Hermanas TM; Schneewind O
    Vaccine; 2011 Sep; 29(38):6572-83. PubMed ID: 21763383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
    Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
    Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
    Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
    Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.
    Verardi PH; Titong A; Hagen CJ
    Hum Vaccin Immunother; 2012 Jul; 8(7):961-70. PubMed ID: 22777090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete Protection Against
    Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
    Front Immunol; 2022; 13():793382. PubMed ID: 35154110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.
    Wang X; Singh AK; Zhang X; Sun W
    Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32152195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
    Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
    [No Abstract]   [Full Text] [Related]  

  • 51. Capturing the natural diversity of the human antibody response against vaccinia virus.
    Lantto J; Haahr Hansen M; Rasmussen SK; Steinaa L; Poulsen TR; Duggan J; Dennis M; Naylor I; Easterbrook L; Bregenholt S; Haurum J; Jensen A
    J Virol; 2011 Feb; 85(4):1820-33. PubMed ID: 21147924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protecting against plague: towards a next-generation vaccine.
    Williamson ED; Oyston PC
    Clin Exp Immunol; 2013 Apr; 172(1):1-8. PubMed ID: 23480179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.
    Eisele NA; Anderson DM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1720-7. PubMed ID: 19828767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.
    Thomas RJ; Webber D; Collinge A; Stagg AJ; Bailey SC; Nunez A; Gates A; Jayasekera PN; Taylor RR; Eley S; Titball RW
    Infect Immun; 2009 Apr; 77(4):1315-23. PubMed ID: 19188359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
    Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
    Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A parenteral DNA vaccine protects against pneumonic plague.
    Yamanaka H; Hoyt T; Yang X; Bowen R; Golden S; Crist K; Becker T; Maddaloni M; Pascual DW
    Vaccine; 2010 Apr; 28(18):3219-30. PubMed ID: 20197132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.
    Medaglia ML; Moussatché N; Nitsche A; Dabrowski PW; Li Y; Damon IK; Lucas CG; Arruda LB; Damaso CR
    J Virol; 2015 Dec; 89(23):11909-25. PubMed ID: 26378174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.
    Arlen PA; Singleton M; Adamovicz JJ; Ding Y; Davoodi-Semiromi A; Daniell H
    Infect Immun; 2008 Aug; 76(8):3640-50. PubMed ID: 18505806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.